SCHEMBL6795221

SCHEMBL6795221

CC(C)(C)OC(=O)N(CCc1ccccn1)c1ccc(NC(=O)c2ccccc2-c2ccc(Cl)cc2)cc1

nearest known ligand 0.51

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
CNR1 P21554 1/20 0.43
NPC1 O15118 2/20 0.42
TSHR P16473 1/20 0.42
SMO Q99835 2/20 0.42
NR3C1 P04150 2/20 0.41
SMN1; SMN2 Q16637 2/20 0.41
RAB9A P51151 1/20 0.41
TP53 P04637 1/20 0.40
TDP1 Q9NUW8 1/20 0.40
LMNA P02545 1/20 0.40
HTT P42858 1/20 0.40
CHRNB2 P17787 1/20 0.39
CHRNB4 P30926 1/20 0.39
CHRNA3 P32297 1/20 0.39
CHRNA4 P43681 1/20 0.39
GAA P10253 2/20 0.39
KDM4E B2RXH2 2/20 0.39
POLB P06746 2/20 0.38
HPGD P15428 1/20 0.38
ALDH1A1 P00352 1/20 0.38

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL6792911 0.93 SMO (0.47) SMOTP53LMNAHTTCHRNB2
SCHEMBL6795007 0.93 SMO (0.48) SMOTP53LMNAHTTCHRNB2
SCHEMBL6793251 0.92 SMO (0.42) SMOLMNAHTTCHRNB2CHRNB4
SCHEMBL6793636 0.92 SMO (0.42) SMOSMN1; SMN2RAB9ALMNAHTT
SCHEMBL6799630 0.92 SMO (0.42) NPC1SMOSMN1; SMN2RAB9ALMNA
SCHEMBL6791610 0.92 SMO (0.42) NPC1SMOSMN1; SMN2RAB9ATP53
SCHEMBL6800714 0.92 SMO (0.42) SMOSMN1; SMN2LMNAHTTCHRNB2
SCHEMBL6791168 0.92 SMO (0.42) SMOLMNAHTTCHRNB2CHRNB4
SCHEMBL6788937 0.92 SMO (0.42) NPC1SMORAB9ALMNAHTT
SCHEMBL6788159 0.92 SMO (0.43) NPC1TSHRSMOSMN1; SMN2RAB9A

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20040058903-A1 Benzamide compounds as apo b secretion inhibitors FUJISAWA PHARMACEUTICAL CO., LTD. (JP) 2004-03-25 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20040058903-A1 Benzamide compounds as apo b secretion inhibitors APOB, APOL1, SCARB1 CNR1 695/4885NPC1 64/4885TSHR 1903/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.